来曲唑降低取卵术后卵巢过度刺激征发生率的临床研究  

The Clinical Effect of Letrozole on Lowering the Ovarian Hyperstimulation Incidence after the Controlled Ovarian Hyperstimulation

作　　者：杜彦[1] 廖月婵[1] 吴日然[1] 

机构地区：[1]广东省中山市博爱医院生殖中心,广东中山528403

出　　处：《中国医学创新》2013年第13期32-34,共3页Medical Innovation of China

摘　　要：目的:探究具有卵巢过度刺激征高危因素患者在取卵术后,用来曲唑降低卵巢过度刺激征(OHSS)发生率的临床效果。方法:选取笔者所在医院生殖中心近一年内行IVF-ET助孕并具有卵巢过度刺激症高危因素的患者86例,于取卵术后口服来曲唑,并系统地回顾既往取卵术后用葡萄糖酸钙推注预防卵巢过度刺激征的资料,对比两种方案下卵巢过度刺激征的发生率以及中、重度OHSS的比例。结果:用来曲唑预防的86例患者中,雌激素水平下降明显,卵巢过度刺激征的发生率为12.79%,中、重度的发生率为2.33%,既往卵巢过度刺激征的发生率为13.02%,中、重度的发生率为4.69%。说明来曲唑可以更好地降低中重度卵巢过度刺激征的发生率。结论:取卵术后服用来曲唑不但可以预防OHSS的发生,而且可以降低中重度OHSS的发生率,可以考虑将来曲唑作为预防卵巢过度刺激征的一线药物使用。Objective： To explore the intrinsic risk factors in patients with ovarian hyperstimuiation oocytes after letrozole to reduce ovarian hyperstimulation （ OHSS ） incidence of clinical effect.Method： A total of 86 high risk patients of OHSS in vitro fertilization cycles were prepared for embryo cryopreservation after oocyte retrieval, the patients in experiment group were treated with oral administration of letrozole after oocyte retrieval, and a systematic review of previous postoperative intravenous of gluconic acid calcium information to prevent ovarian hyperstimulation, the proportion of the incidence of OHSS of the comparison of the two programs, as well as in moderate and severe OHSS.Result： Of 86 patients in the letrozole prevention, estradiol levels decreased significantly, 12.79% of the incidence of ovarian hyperstimulation, moderate and severe incidence was 2.33%, 13.02% of the incidence of previous ovarian hyperstimulation moderate and severe incidence was 4.69%.Description letrozole can reduce the incidence of ovarian hyperstimulation.Conclusion： Providing letrozole for the high risk patients of OHSS after oocyte retrieval not only can prevent the occurrence of OHSS but also can reduce the incidence of moderate and severe OHSS.Letrozole can be used in the later clinical practice as the prevention of ovarian hyperstimulation.

关 键 词：来曲唑 卵巢过度刺激征 发生率 取卵术 高危因素 

分 类 号：R714.8[医药卫生—妇产科学]